Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy

Dermatology Online Journal

Volumn 13, Issue 4, 2007, Pages

  Gay, Hiram A ^a   Cavalieri, Ronaldo ^b   Allison, Ron R ^a   Finley, James ^a   Quan Jr , Walter D ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER RADIOTHERAPY; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DRUG INTERMITTENT THERAPY; ELECTRON THERAPY; HUMAN; KIDNEY CARCINOMA; MALE; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE FRACTIONATION; SKIN METASTASIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; FACE TUMOR; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; REMISSION; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FACIAL NEOPLASMS; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; PYRIDINES; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 36448986719     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Brownstein MH, Helwig EB. Metastatic tumors of the skin. Cancer 1972;29(5):1298-307.
2. Koga S, Tsuda S, Nishikido M, Matsuya F, Saito Y, Kanetake H. Renal cell carcinoma metastatic to the skin. Anticancer Res 2000;20(3B):1939-40.
3. Lim C, Chan R, Regan W. Renal cell carcinoma with cutaneous metastases. Australas J Dermatol 2005;46(3):158-60.
4. Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol 1995;33(2 Pt 1):161-82; quiz 83-6.
5. Porter NA, Anderson HL, Al-Dujaily S. Renal cell carcinoma presenting as a solitary cutaneous facial metastasis: case report and review of the literature. Int Semin Surg Oncol 2006;3:27.
6. Perdona S, Autorino R, Gallo L, et al. Renal cell carcinoma with solitary toe metastasis. Int J Urol 2005;12(4):401-4.
7. Svedman C, Sandstrom P, Pisa P, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006;45(7):870-5.
8. Wersall PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005;77(1):88-95.
9. Muacevic A, Kreth FW, Mack A, Tonn JC, Wowra B. Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim Invasive Neurosurg 2004;47(4):203-8.
10. Noel G, Valery CA, Boisserie G, et al. LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urol Oncol 2004;22(1):25-31.
11. Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000;48(5):1389-93.
12. Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998;83(2):344-53.
13. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005;75(1):9-17.
14. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109.
15. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12.
16. Escudier B, et al., Randomized phase II trial of the raf kinase and vegf inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol, 2005. 23(16S):4510 .
17. Escudier B, et al., Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (ifn) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2006. 24(18S): 4501 (abstract)